Evidence map›Paper›PMID 37575721›Full record

ReviewCureus2023

Stem Cell Therapy in Critical Limb Ischemia.

Madhan Jeyaraman, Somumurthy Nagarajan, Nicola Maffulli, Packkyarathinam R P, Naveen Jeyaraman, Arulkumar N, Manish Khanna, Sankalp Yadav, Ashim Gupta

Open access · diamondAbstract readReview
In one paragraph

Review in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Diabetic foot attack: Managing severe sepsis in the diabetic patient.World journal of critical care medicine · 2025
    Article
  4. Review
  5. Article
  6. Mesenchymal stromal cell therapy (REGENACIPStem cell research & therapy · 2024
    Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Madhan JeyaramanOrthopaedics, ACS Medical College and Hospital, Dr. MGR Educational and Research Institute, Chennai, IND.
Somumurthy NagarajanOrthopaedic Rheumatology, Dr. Ram Manohar Lohiya National Law University, Lucknow, IND.
Nicola MaffulliOrthopedics, School of Medicine and Surgery, University of Salerno, Fisciano, ITA.
Packkyarathinam R PRegenerative Medicine, Indian Stem Cell Study Group Association, Lucknow, IND.
Naveen JeyaramanOrthopaedics, ACS Medical College and Hospital, Dr. MGR Educational and Research Institute, Chennai, IND.
Arulkumar NOrthopaedics, ACS Medical College and Hospital, Dr. MGR Educational and Research Institute, Chennai, IND.
Manish KhannaRegenerative Medicine, Indian Stem Cell Study Group Association, Lucknow, IND.
Sankalp YadavInternal Medicine, Shri Madan Lal Khurana Chest Clinic, New Delhi, IND.
Ashim GuptaRegenerative Medicine, Indian Stem Cell Study Group Association, Lucknow, IND.
Indian Institute of Management Lucknow · INACS Medical College and Hospital · INDr. Ram Manohar Lohia National Law University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Critical limb ischemia (CLI), a serious outcome of peripheral artery disease, is frequently associated with morbid outcomes. The available treatment modalities do not provide satisfactory results, leading to marked morbidities such as joint contracture and amputations, resulting in a high economic burden. The peripheral vascular disease tends to cause more morbidity in patients with diabetes and atherosclerosis, given the pre-existing compromised perfusion of medium and small vessels in diabetic patients. With surgical procedures, the chance of vascular compromise further increases, inducing a significantly greater rate of amputation. Hence, the need for nonsurgical treatment modalities such as stem cell therapy (SCT), which promotes angiogenesis, is warranted. In CLI, SCT acts through neovascularization and the development of collateral arteries, which increases blood supply to the soft tissues of the ischemic limb, providing satisfactory outcomes. An electronic database search was performed in PubMed, SCOPUS, EMBASE, and ScienceDirect to identify published clinical trial data, research studies, and review articles on stem cell therapy in critical limb ischemia. The search resulted in a total of 2391 results. Duplicate articles screening resulted in 565 articles. In-depth screening of abstracts and research titles excluded 520 articles, yielding 45 articles suitable for full-text review. On review of full text, articles with overlapping and similar results were filtered, ending in 25 articles. SCT promotes arteriogenesis, and bone marrow-derived mesenchymal stromal cells produce significant effects like reduced morbidity, improved amputation-free survival (AFS ) rate, and improved distal perfusion even in "no-option" CLI patients. SCT is a promising treatment modality for CLI patients, even in those in whom endovascular and revascularization procedures are impossible. SCT assures a prolonged AFS rate, improved distal perfusion, improved walking distances, reduced amputation rates, and increased survival ratio, and is well-tolerated.

Indexed as

amputation ratescritical limb ischemiaischemiamononuclear cellsstem cell

Identifiers

PMID37575721
PMCPMC10416751
OpenAlexW4384029356

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.